- Guang-Wen Cao, MD
- Professor and Chairman, Department of epidemiology, Second Military Medical University, Shanghai 200433, China.
Special Issue Introduction
Hepatocellular carcinoma (HCC) is the second leading cause of cancer death in males worldwide. Surgical treatment, namely radical surgery and liver transplantation, remains to be the mainstay of the treatment. However, postoperative recurrence frequently occurs. The majority of HCC patients may not get the opportunity to receive the treatment due to being diagnosed at the late stage. Thus, active prophylaxis targeted to the cause of this malignancy is getting more and more important. As chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) is the leading cause of HCC worldwide, it is important to identify what kinds of HBV- or HCV-infected subjects are more likely to develop HCC and need specific prophylactic options before the occurrence of HCC. In addition, with more in-depth research and the application of advanced technology, the knowledge about the prevention of HCC occurrence and postoperative recurrence is making great progress. Antiviral treatment and immunotherapy to prevent or postpone the postoperative recurrence should be highlighted. It is important to summarize and understand the new development on active prophylaxis of HCC occurrence and recurrence in the high-risk populations. From this aspect, this special issue was established to introduce the novel understanding with solid evidence for the prophylaxis of HCC occurrence and postoperative recurrence.
Submission Deadline30 Sep 2020